O Rascol

Summary

Country: France

Publications

  1. ncbi Development of dyskinesias in a 5-year trial of ropinirole and L-dopa
    Olivier Rascol
    Clinical Investigation Centre, Department of Pharmacology and INSERM U455, Toulouse Hospital, Toulouse, France
    Mov Disord 21:1844-50. 2006
  2. ncbi Monoamine oxidase inhibitors--is it time to up the TEMPO?
    Olivier Rascol
    Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U 455, Toulouse University Hospital, France
    Lancet Neurol 2:142-3. 2003
  3. ncbi Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
    O Rascol
    Clinical Investigation Centre, Department of Clinical Pharmacology, University Hospital, Toulouse, France
    Lancet 365:947-54. 2005
  4. ncbi A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease
    Olivier Rascol
    Department of Clinical Pharmacology, Hospital and University Paul Sabatier of Toulouse, France
    Fundam Clin Pharmacol 26:557-64. 2012
  5. ncbi Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial
    O Rascol
    Department of Clinical Pharmacology and Neurosciences, INSERM CIC9302 and UMR835, University Hospital and University of Toulouse, 37 Allees Jules Guesde, 31000 Toulouse, France
    Parkinsonism Relat Disord 18:370-6. 2012
  6. ncbi Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study
    Olivier Rascol
    Department of Clinical Pharmacology, INSERM Clinical Investigation Center CIC 9302 and UMR 825, CHU Toulouse Purpan and University Paul Sabatier, Toulouse, France
    Mov Disord 25:368-76. 2010
  7. ncbi The management of patients with early Parkinson's disease
    O Rascol
    Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, Toulouse University Hospital, Toulouse, France
    Parkinsonism Relat Disord 9:61-7. 2002
  8. ncbi 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders
    Olivier Rascol
    INSERM CIC P302 and UMR 825, Department of Clinical Pharmacology, Faculte de Medecine, CHU and University UPS of Toulouse, Toulouse, France
    Mov Disord 24:S732-41. 2009
  9. ncbi Rotigotine transdermal delivery for the treatment of Parkinson's disease
    Olivier Rascol
    Clinical Investigation Center and Neurosciences Institute, Department of Clinical Pharmacology, Faculty of Medicine, INSERM U 825, Toulouse, France
    Expert Opin Pharmacother 10:677-91. 2009
  10. ncbi "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design
    Olivier Rascol
    Clinical Investigation Center, Department of Neurosciences, University Hospital of Toulouse, INSERM UMR 825, Toulouse, France
    Neurology 72:S51-8. 2009

Detail Information

Publications92

  1. ncbi Development of dyskinesias in a 5-year trial of ropinirole and L-dopa
    Olivier Rascol
    Clinical Investigation Centre, Department of Pharmacology and INSERM U455, Toulouse Hospital, Toulouse, France
    Mov Disord 21:1844-50. 2006
    ..Early use of ropinirole postpones the onset of dyskinesias, but these benefits decline when levodopa therapy is started, with no evidence of a subsequent rapid "catch-up" or a persisting preventive effect...
  2. ncbi Monoamine oxidase inhibitors--is it time to up the TEMPO?
    Olivier Rascol
    Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U 455, Toulouse University Hospital, France
    Lancet Neurol 2:142-3. 2003
  3. ncbi Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
    O Rascol
    Clinical Investigation Centre, Department of Clinical Pharmacology, University Hospital, Toulouse, France
    Lancet 365:947-54. 2005
    ..This study investigated rasagiline efficacy and safety in levodopa-treated patients with Parkinson's disease and motor fluctuations...
  4. ncbi A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease
    Olivier Rascol
    Department of Clinical Pharmacology, Hospital and University Paul Sabatier of Toulouse, France
    Fundam Clin Pharmacol 26:557-64. 2012
    ..These pilot findings are consistent with preclinical data in primates and support the hypothesis that naftazone may have antiparkinsonian and antidyskinetic effects in humans that deserve further clinical investigation...
  5. ncbi Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial
    O Rascol
    Department of Clinical Pharmacology and Neurosciences, INSERM CIC9302 and UMR835, University Hospital and University of Toulouse, 37 Allees Jules Guesde, 31000 Toulouse, France
    Parkinsonism Relat Disord 18:370-6. 2012
    ..To determine the efficacy and safety of pardoprunox in levodopa-treated patients with Parkinson's disease (PD) experiencing motor fluctuations...
  6. ncbi Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study
    Olivier Rascol
    Department of Clinical Pharmacology, INSERM Clinical Investigation Center CIC 9302 and UMR 825, CHU Toulouse Purpan and University Paul Sabatier, Toulouse, France
    Mov Disord 25:368-76. 2010
    ..A single dose of up to 60 mg of S90049 given sublingually was superior to placebo in improving UPDRS III and aborting a practical OFF in patients with advanced PD. Testing greater doses might improve response rate...
  7. ncbi The management of patients with early Parkinson's disease
    O Rascol
    Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, Toulouse University Hospital, Toulouse, France
    Parkinsonism Relat Disord 9:61-7. 2002
    ..Integrating individual clinical expertise to the best available external clinical evidence (evidence-based medicine) is the best strategy in making decisions about the care of individual patients...
  8. ncbi 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders
    Olivier Rascol
    INSERM CIC P302 and UMR 825, Department of Clinical Pharmacology, Faculte de Medecine, CHU and University UPS of Toulouse, Toulouse, France
    Mov Disord 24:S732-41. 2009
    ..Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy...
  9. ncbi Rotigotine transdermal delivery for the treatment of Parkinson's disease
    Olivier Rascol
    Clinical Investigation Center and Neurosciences Institute, Department of Clinical Pharmacology, Faculty of Medicine, INSERM U 825, Toulouse, France
    Expert Opin Pharmacother 10:677-91. 2009
    ..An interesting element of this profile is constant drug delivery, which may avoid pulsatile dopaminergic stimulation, which has been postulated to be related to the development of motor complications...
  10. ncbi "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design
    Olivier Rascol
    Clinical Investigation Center, Department of Neurosciences, University Hospital of Toulouse, INSERM UMR 825, Toulouse, France
    Neurology 72:S51-8. 2009
    ..To observe clinically relevant changes, several years of follow-up is required, and controlled, randomized, pragmatic trials should be considered when establishing clinical development plans...
  11. ncbi [Treatments in the early stage of Parkinson disease]
    O Rascol
    Laboratoire de Pharmacologie Clinique, Centre d'Investigation Clinique, INSERM U825, , Centre Hospitalier Universitaire, Toulouse
    Rev Neurol (Paris) 164:F77-84. 2008
  12. ncbi Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study
    Olivier Rascol
    Laboratoire de Pharmacologie Medicale et Clinique, Pole NeuroSciences, Centre d Investigations Cliniques, Institut National de la Sante et de la Recherche Medicale, Unité 825, University Hospital, Toulouse, France
    Arch Neurol 65:577-83. 2008
    ..To assess the safety and efficacy of tesofensine, a triple monoamine reuptake inhibitor, in patients with advanced Parkinson disease (PD)...
  13. ncbi Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study
    Olivier Rascol
    INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculte de Medecine, Toulouse, France
    Mov Disord 21:2110-5. 2006
    ..001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy...
  14. ncbi Rasagiline in the pharmacotherapy of Parkinson's disease--a review
    Olivier Rascol
    Department of Clinical Pharmacology, Clinical Investigation Center and Neurosciences Institute, Faculty of Medicine, 37 Allees Jules Guesde, Toulouse 31073, France
    Expert Opin Pharmacother 6:2061-75. 2005
    ..This article outlines the evidence surrounding the efficacy and safety of rasagiline, and discusses its potential to address some of the currently unmet needs of Parkinson's disease therapy...
  15. ncbi Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease
    Olivier Rascol
    Departments of Clinical Pharmacology and Neurosciences, Toulouse University Hospital, INSERM CIC9302 UMR825 Toulouse, France
    Mov Disord 25:2326-32. 2010
    ..Pramipexole ER was not equivalent to IR, but the difference was marginal. The fact that >80% of the patients successfully switched overnight at unchanged dosage shows that this practice was feasible in most patients...
  16. ncbi Treatment interventions for Parkinson's disease: an evidence based assessment
    Olivier Rascol
    Clinical Investigation Centre and the Department of Clinical Pharmacology, INSERM U 455, Toulouse University Hospital, 31073 Toulouse Cedex, France
    Lancet 359:1589-98. 2002
    ..We hope that our review will help doctors to incorporate this background into their own decision-making strategy to make appropriate choices with respect to the treatment of individual patients with Parkinson's disease...
  17. ncbi Milestones in Parkinson's disease therapeutics
    Olivier Rascol
    Department of Clinical Pharmacology, University Hospital of Toulouse, France
    Mov Disord 26:1072-82. 2011
    ..Newer molecular targets, new animal models, novel clinical trial designs, and biomarkers to assess disease modification have created hope for future therapeutic interventions...
  18. ncbi Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease
    O Rascol
    Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medecine, 37 Allees Jules Guesde, 31073 Toulouse Cedex, France
    Arch Neurol 58:249-54. 2001
    ..Dyskinesias are a frequent adverse effect of long-term levodopa therapy. The relative contribution of dopamine D(1) and D(2) receptor function to the pathophysiology of levodopa-induced dyskinesias remains a matter of controversy...
  19. ncbi The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease
    O Rascol
    Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Toulouse, France
    J Neurol 247:II51-7. 2000
    ..This seems to be best achieved by the use of D2 dopamine agonists in the early stages of the disease, before, or in combination with, levodopa...
  20. ncbi Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
    O Rascol
    Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France
    Mov Disord 16:708-13. 2001
    ..Further studies are required to assess whether this property could have potential therapeutic applications in the long-term management of dyskinetic patients with Parkinson's disease...
  21. ncbi A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
    Olivier Rascol
    Department of Clinical Pharmacology, Faculty of Medicine, Toulouse, France
    Lancet Neurol 10:415-23. 2011
    ..Rasagiline 1 mg per day, but not 2 mg per day, was shown to be efficacious in the primary analysis. Here, we report additional secondary and post-hoc analyses of the ADAGIO study...
  22. ncbi A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group
    O Rascol
    Clinical Investigation Center, Neuropharmacology Unit, INSERM Unité 455, University Hospital, Toulouse, France
    N Engl J Med 342:1484-91. 2000
    ..There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist...
  23. ncbi Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release
    O Rascol
    Department of Clinical Pharmacology and Neurosciences, INSERM U825 and Clinical Investigation Center, University Hospital, Toulouse, France
    Eur J Neurol 18:3-10. 2011
    ..Once-daily administration is convenient and may improve compliance. Other theoretical advantages in terms of efficacy or tolerability deserve further exploration...
  24. ncbi Motor activation in multiple system atrophy and Parkinson disease: a PET study
    P Payoux
    INSERM, Imagerie cérébrale et handicaps neurologiques UMR 825, Toulouse, France
    Neurology 75:1174-80. 2010
    ..We assessed right hand motor activation in patients with MSA before and after an acute levodopa challenge in comparison with patients with PD and healthy volunteers (HVs)...
  25. ncbi Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPaMiP study
    Laurence Negre-Pages
    Department of Clinical Pharmacology, University Hospital, Toulouse, France
    Mov Disord 25:157-66. 2010
    ..Both symptoms were commonly associated in the same PD patients, but were correlated with different clinical/therapeutic features, suggesting different underlying pathophysiological mechanisms...
  26. ncbi Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study
    J L Montastruc
    Service de Pharmacologie Clinique, , , , Toulouse, France
    Clin Neuropharmacol 24:181-3. 2001
    ..Because a relationship between sleep attacks and not only ropinirole but also bromocriptine treatment was described, the present work suggests that sleep attacks are a common side effect of all dopamine agonists...
  27. ncbi Amitriptyline treatment in chronic drug-induced headache: a double-blind comparative pilot study
    S Descombes
    Centre d'Investigation Clinique, , Purpan Cedex, France
    Headache 41:178-82. 2001
    ..CONCLUSION: This pilot study suggests a beneficial effect of amitriptyline on headache frequency and quality of life for patients with chronic drug-induced headache...
  28. ncbi Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease
    S Descombes
    Clinical Investigation Center, INSERM U455, Toulouse, France
    Neurology 56:1239-42. 2001
    ....
  29. ncbi Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke
    J Pariente
    , unit U455, , Toulouse, France
    Ann Neurol 50:718-29. 2001
    ..This redistribution of activation toward the motor cortex output activation was associated with an enhancement of motor performance...
  30. ncbi Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study
    A Gerdelat-Mas
    Fédération de Neuroscience, Hopital Purpan, Toulouse, France
    J Neurol Neurosurg Psychiatry 78:1140-2. 2007
    ..Experimental data have indicated the involvement of basal ganglia and dopaminergic pathways in central nociceptive processing...
  31. ncbi The management of patients with early Parkinson's disease
    Olivier Rascol
    Department of Clinical Pharmacology and Pharmacovigilance, Clinical Investigations Centre, INSERM, Toulouse, France
    Adv Neurol 91:203-11. 2003
  32. ncbi Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey
    Laurence Negre-Pages
    Department of Clinical Pharmacology, University Hospital, Toulouse, France
    Mov Disord 23:1361-9. 2008
    ..9; 95% CI 1.2-3.2). Chronic pain is frequent but underreported in PD. Awareness of this problem should be increased and the assessment of analgesic strategies improved...
  33. ncbi [Management of levodopa-induced dyskinesia]
    O Rascol
    Service de Pharmacologie, , Centre d'Investigations Cliniques, INSERM U455, 37, , 31073 Toulouse, France
    Rev Neurol (Paris) 158:S117-24. 2002
    ....
  34. ncbi Within-session and between-session reproducibility of cerebral sensorimotor activation: a test--retest effect evidenced with functional magnetic resonance imaging
    I Loubinoux
    INSERM U455, , Toulouse, France
    J Cereb Blood Flow Metab 21:592-607. 2001
    ..Furthermore, the pattern observed in the fMRI signal changes might evoke a consolidation process...
  35. ncbi Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects
    A Gerdelat-Mas
    INSERM U 455, Toulouse, France
    Neuroimage 27:314-22. 2005
    ....
  36. ncbi Dyskinesia: L-dopa-induced and tardive dyskinesia
    O Rascol
    Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U 455, Toulouse University-Hospital, 37 allees J. Guesde, 31073 Toulouse Cedex, France
    Clin Neuropharmacol 24:313-23. 2001
    ....
  37. ncbi Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management
    J M Senard
    Laboratory of Medical and Clinical Pharmacology, INSERM U317, Faculty of Medicine, Paul Sabatier University, Toulouse, France
    Drugs Aging 18:495-505. 2001
    ..Other drugs such as desmopressin or octreotide may be of interest in some situations. Domperidone is widely used in patients with parkinsonism with no proven effect on orthostatic hypotension...
  38. ncbi Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
    J L Montastruc
    Service de Pharmacologie Clinique, centre Midi Pyrénées de pharmacovigilance, de Pharmacoépidémiologie et d Informations sur le Médicament and Centre d Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France
    Mov Disord 16:511-4. 2001
    ..71-1.95]), in group D (0.98 [0.42-1.93]), or in group B/D (1.53 [0.70-2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone...
  39. ncbi Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease
    Frederic Courbon
    Service de Medecine Nucleaire, University Rangueil Hospital, Toulouse, France
    Mov Disord 18:890-7. 2003
    ..Our results suggest that MIBG myocardial scintigraphy (analysis of both H/M ratio and regional MIBG uptake) may be more sensitive than standard autonomic testing for the early detection of silent autonomic dysfunction in PD...
  40. ncbi [Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance]
    Jean Louis Montastruc
    Laboratoire de Pharmacologie Medicale et Clinique, Unité de Pharmacoépidémiologie, UA 3696, IFR 126, Universite Paul Sabatier, Faculte de Medecine, Toulouse, France
    Therapie 61:29-38. 2006
    ..It is also an important mediator for pleasure, hedonic regulations and sexual behaviour. This review also underlines the major role of spontaneous reports to the pharmacovigilance systems to identify new adverse drug reactions...
  41. ncbi Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study
    Christine Brefel-Courbon
    Service de Pharmacologie Clinique, University Hospital, Toulouse, France
    Mov Disord 20:1557-63. 2005
    ..This study shows that pain threshold is lower in PD patients but returns to normal ranges after levodopa administration. Moreover, PD patients have higher pain-induced activation in nociceptive pathways, which can be reduced by levodopa...
  42. ncbi Clinical and economic analysis of spa therapy in Parkinson's disease
    Christine Brefel-Courbon
    Service de Pharmacologie Clinique, Laboratoire de Médecine Thermale, University Hospital, Toulouse, France
    Mov Disord 18:578-84. 2003
    ..This cost-effectiveness analysis suggests that spa therapy is more effective and less expensive than conventional treatment alone and could be beneficial in the management of PD...
  43. ncbi Deep brain stimulation for parkinson's disease: correlation between intraoperative subthalamic nucleus neurophysiology and most effective contacts
    P Cintas
    Department of Neurosciences, CHU Toulouse, University Paul Sabatier, Toulouse, France
    Stereotact Funct Neurosurg 80:108-13. 2003
    ..Interestingly, at 3 months, the same electrode contact was maximally efficient for rigidity, akinesia and tremor in only 13 of the 39 cases. This lack of correlation did not affect the global improvement...
  44. ncbi Contrasting changes in cortical activation induced by acute high-frequency stimulation within the globus pallidus in Parkinson's disease
    Pierre Payoux
    INSERM, U 825, CHU Toulouse, Toulouse, France
    J Cereb Blood Flow Metab 29:235-43. 2009
    ....
  45. ncbi Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort
    S Perez-Lloret
    Department of Clinical Pharmacology, University Hospital and University of Toulouse, Toulouse, France
    Eur J Neurol 19:28-37. 2012
    ..Abnormal oro-buccal functions including dysarthria, sialorrhea and dysphagia commonly affect patients with Parkinson's disease (PD)...
  46. ncbi Deficit of verb generation in nondemented patients with Parkinson's disease
    Patrice Peran
    Institut National de la Santé et de la Recherche Médicale U 455, Centre Hospitalier Universitaire Purpan, Toulouse, France
    Mov Disord 18:150-6. 2003
    ..The specific deficit for verb production in PD patients is discussed in relation to deficits affecting either action or grammatical representations...
  47. ncbi Does ageing influence deep brain stimulation outcomes in Parkinson's disease?
    Fabienne Ory-Magne
    Department of Neurology, University Hospital CHU, Toulouse, France
    Mov Disord 22:1457-63. 2007
    ..A longer follow-up duration and a larger population seem necessary to better assess the quality of life perception in elderly patients and to determinate the real risk of hemorrage...
  48. ncbi Object naming and action-verb generation in Parkinson's disease: a fMRI study
    Patrice Peran
    Department of Radiology, I R C C S Santa Lucia Foundation, Rome, Italy INSERM U825, Toulouse, France
    Cortex 45:960-71. 2009
    ..The aim of this study was to investigate the "motor" theory by exploring the neuronal substrates of action-related word production...
  49. ncbi Transdermal delivery of dopaminergic agents
    Olivier Rascol
    Clinical Investigation Centre, Toulouse University Hospital, Toulouse, France
    Neurology 65:S1-2. 2005
  50. ncbi Transmission of group II heteronymous pathways is enhanced in rigid lower limb of de novo patients with Parkinson's disease
    M Simonetta Moreau
    INSERM U455, centre d investigation clinique, Pavillon Riser, CHU Purpan, Place du Dr Baylac, 31059 Toulouse, France
    Brain 125:2125-33. 2002
    ....
  51. ncbi Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects
    Isabelle Loubinoux
    INSERM U455, Pavilion Riser, Hopital Purpan, 31059 Toulouse, France
    Neuropsychologia 40:1815-21. 2002
    ..This S1M1 hyperactivation is likely to be responsible for the better performance. The brain effect and motor improvement were dose dependent. For both, 20 mg was the optimal dose...
  52. ncbi Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer
    Isabelle Loubinoux
    INSERM U455, Pavillon Riser, Hopital Purpan, 31059 Toulouse, France
    Neuroimage 27:299-313. 2005
    ..An improvement in both behavior and cerebral efficiency was suggested. It could be hypothesized that monoamines, by an unspecific effect, may tune the response of pyramidal neurons to optimize performances...
  53. ncbi Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease
    Claire Thalamas
    Clinical Investigation Center, Department of Clinical Pharmacology, University Hospital, Toulouse, France
    Clin Neuropharmacol 28:120-5. 2005
    ..This prolonged half-life is of particular interest, given the current hypothesis that more continuous dopaminergic receptor stimulation may reduce motor complications in patients with Parkinson disease...
  54. ncbi A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects
    Isabelle Loubinoux
    INSERM U455, Pavillon Riser, Hopital Purpan, 31059 Toulouse, France
    Neuroimage 15:26-36. 2002
    ..Paroxetine dose-dependently modulates activation of the entire motor pathway in a way that favors motor output. Thus, a single dose of the SSRI paroxetine reorganized motor processing...
  55. ncbi Clinical phenotype and neuroimaging findings in a French family with hereditary ferritinopathy (FTL498-499InsTC)
    Fabienne Ory-Magne
    Department of Neurosciences, University Hospital of Toulouse, France
    Mov Disord 24:1676-83. 2009
    ....
  56. ncbi Cortical motor activation in akinetic schizophrenic patients: a pilot functional MRI study
    Pierre Payoux
    INSERM U 455, and PET Center, University Hospital of Toulouse, France
    Mov Disord 19:83-90. 2004
    ..SMA was hypoactive in akinetic schizophrenic patients, emphasizing the role of this area in motor slowness. Other abnormal signals likely reflect schizophrenia-related abnormal intracortical connections...
  57. ncbi Methylphenidate modulates cerebral post-stroke reorganization
    Jean Tardy
    INSERM U455, Pavillon Riser, Purpan Hospital, Toulouse, France
    Neuroimage 33:913-22. 2006
    ..We hypothesized that a single dose of methylphenidate (MP) would modulate cerebral motor activation and behavior in patients having suffered a subcortical stroke...
  58. ncbi Adverse drug reactions to dopamine agonists: a comparative study in the French Pharmacovigilance Database
    Santiago Perez-Lloret
    Service de Pharmacologie Clinique, EA 3696, INSERM CIC9023, UMR 825, Faculte de Medecine, Centre Hospitalier Universitaire et Université de Toulouse, Toulouse, France
    Mov Disord 25:1876-80. 2010
    ..001). Somnolence or ICD reports were less frequent with levodopa, whereas confusion was more frequently reported. In summary, our data show significant differences in the kind of ADRs reported for each DA...
  59. ncbi A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy
    M B Delisle
    Neuropathology Laboratory, INSERM U466, University Hospital, University Paul Sabatier, Toulouse, France
    Acta Neuropathol 98:62-77. 1999
    ..Our results suggest that the N279K mutation affects splicing similar to the intronic mutations, allowing exon 10 to be incorporated more frequently in the Tau transcript...
  60. ncbi Safety of rasagiline for the treatment of Parkinson's disease
    Santiago Perez-Lloret
    Department of Clinical Pharmacology, Faculty of Medicine, Toulouse, France
    Expert Opin Drug Saf 10:633-43. 2011
    ..Drug interaction should be monitored. The risk of serotonin toxicity with serotoninergic antidepressants remains insufficiently characterized, while current available data in small groups of subjects suggest a low risk...
  61. ncbi Subthalamic nucleus stimulation reduces abnormal motor cortical overactivity in Parkinson disease
    Pierre Payoux
    Institut National de la Santé et de la Recherche Médicale U455, Toulouse, France
    Arch Neurol 61:1307-13. 2004
    ....
  62. ncbi Cerebral autoregulation is preserved in multiple system atrophy: A transcranial Doppler study
    Anne Pavy-Le Traon
    Laboratory of Autonomic Nervous System and Neurosonology, Vascular Neurology Department, Hopital Rangueil, Toulouse, France
    Mov Disord 21:2122-6. 2006
    ..Changes in CR reflecting the rate of autoregulation, when standing did not differ between the two groups. These data suggest that dynamic cerebral autoregulation is preserved in MSA...
  63. ncbi Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study
    Marc Ziegler
    , , Paris, France
    Mov Disord 18:418-25. 2003
    ....
  64. ncbi Limitations of current Parkinson's disease therapy
    Olivier Rascol
    Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France
    Ann Neurol 53:S3-12; discussion S12-5. 2003
    ..Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety...
  65. ncbi Levodopa in the treatment of Parkinson's disease: current controversies
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mov Disord 19:997-1005. 2004
    ..Clinical trials to test this hypothesis are underway. We review current evidence relating to these areas of controversy...
  66. ncbi Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA
    Clin Neuropharmacol 27:58-62. 2004
  67. ncbi Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
    Alan L Whone
    Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 54:93-101. 2003
    ..1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by (18)F-dopa PET...
  68. ncbi Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial
    Christopher G Goetz
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 22:179-86. 2007
    ..Sarizotan 2 mg/day is a safe agent in PD patients with dyskinesia. To test its role in abating dyskinesia, future studies should focus on this dose and will use the composite score of UPDRS Items 32+33 as the primary outcome...
  69. ncbi How much phenotypic variation can be attributed to parkin genotype?
    Ebba Lohmann
    INSERM U289, Hopital de la Salpetriere, Paris, France
    Ann Neurol 54:176-85. 2003
    ..Patients with a single heterozygous mutation had significantly later and more asymmetrical onset and more frequent levodopa-induced fluctuations and dystonia than patients with two mutations...
  70. ncbi Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia
    Philippe Damier
    Centre Hospitalier Universitaire de Nantes, centre d investigation clinique, Nantes, France
    Arch Gen Psychiatry 64:170-6. 2007
    ..Tardive dyskinesia (TD) is a common and potentially disabling disorder induced by use of antipsychotic drugs for which medical treatment often gives disappointing results...
  71. ncbi Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
    Christopher G Goetz
    Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 20:523-39. 2005
    ..We consider a 3-year period a reasonable time frame for published updates and are working to establish a Web-based mechanism to update the report in an ongoing manner...
  72. ncbi Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial
    Werner H Poewe
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Lancet Neurol 6:513-20. 2007
    ....
  73. ncbi Skin cancers and precancerous lesions in Parkinson's disease patients
    Joaquim Ferreira
    Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal
    Mov Disord 22:1471-5. 2007
    ..The frequency of actinic keratosis in PD patients and the associated risk to develop melanoma recommends its screening in future epidemiological studies...
  74. ncbi Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)
    Gregor K Wenning
    Department of Neurology, University of Innsbruck, Austria
    Mov Disord 19:1391-402. 2004
    ..Based on our findings, the UMSARS appears to be a multidimensional, reliable, and valid scale for semiquantitative clinical assessments of MSA patients...
  75. ncbi Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 22:2409-17. 2007
    ..Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long-term complications. Both ropinirole and levodopa are viable treatment options in early PD...
  76. ncbi Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study
    Jan C M Zijlmans
    National Hospital for Neurology and Neurosurgery, London, United Kingdom
    Mov Disord 19:1006-1011. 2004
    ..Thus, apomorphine may be safely administered to patients receiving therapy with levodopa and entacapone, providing a useful addition to treatment for patients with advanced Parkinson's disease...
  77. ncbi Dopaminagonists and fibrotic valvular heart disease: further considerations
    Olivier Rascol
    Mov Disord 19:1524-5. 2004
  78. ncbi Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations
    Christopher G Goetz
    Rush University Medical Center, 1725 W Harrison Street, Chicago, IL 60612, USA
    Mov Disord 19:1020-8. 2004
    ..5 increments, this adaptation warrants clinimetric testing. Without such testing, however, the original five-point scales should be maintained...
  79. ncbi Trimetazidine: a new cause for drug-induced parkinsonism?
    Agnes Sommet
    Mov Disord 20:1080-1. 2005
  80. ncbi Atypical parkinsonism and Annonaceae consumption in New Caledonia
    Gilles Angibaud
    Mov Disord 19:603-4. 2004
  81. ncbi New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance
    Olivier Rascol
    Mov Disord 19:611-3. 2004
  82. ncbi Assessing the risk of a necessary harm: placebo surgery in Parkinson disease
    Olivier Rascol
    Neurology 65:982-3. 2005
  83. ncbi Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need
    Olivier Rascol
    Mov Disord 21:1059-61. 2006
  84. ncbi Scales to assess psychosis in Parkinson's disease: Critique and recommendations
    Hubert H Fernandez
    Department of Neurology, McKnight Brain Institute University of Florida, Gainesville, Florida 32611, USA
    Mov Disord 23:484-500. 2008
    ..The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time...
  85. ncbi Neuroprotection: Present and future
    Regis Bordet
    EA1046 Département de Pharmacologie Médicale, Institut de Médecine Prédictive et de Recherche Thérapeutique, Faculté de Médecine de l Université Lille 2 and Centre Hospitalier et Universitaire de Lille, Lille, France
    Therapie 62:473-6. 2007
    ..The formalization of disease modification prompts several lines of thought, which are developed in the present article...
  86. ncbi Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study
    Stephane Thobois
    Service de Neurologie D and Cycloton Unit, CERMEP, Hopital Neurologique Pierre Wertheimer, Lyon, France
    Arch Neurol 60:713-8. 2003
    ..Mutations of the parkin gene are frequently encountered in patients with young-onset Parkinson disease (YOPD), but the effects of this mutation on the nigrostriatal dopaminergic degeneration are not well established...
  87. ncbi Dementia with Lewy bodies and Parkinson disease with dementia: can MRI make the difference?
    Klaus Seppi
    Neurology 69:717-8. 2007
  88. ncbi Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study
    Bjorn Holmberg
    Movement Disorders Unit, Sahlgrenska University Hospital, Goteborg University, Goteborg, Sweden
    Mov Disord 22:1138-44. 2007
    ..In conclusion, r-hGH administration in MSA patients for up to 1 year appears safe and might influence disease symptoms, signs and, possibly, progression. The results support further studies utilizing higher doses in more patients...
  89. ncbi Depression rating scales in Parkinson's disease: critique and recommendations
    Anette Schrag
    University Department of Clinical Neurosciences, Royal Free and University College Medical School, London, UK
    Mov Disord 22:1077-92. 2007
    ..The complex and time-consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted...
  90. ncbi Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan
    Christopher G Goetz
    Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 22:41-7. 2007
    ....
  91. ncbi Placebo influences on dyskinesia in Parkinson's disease
    Christopher G Goetz
    Rush University Medical Center, Chicago, Illinois, USA
    Mov Disord 23:700-7. 2008
    ..The magnitude and variance of placebo-related changes and the factors that influence them can be helpful in the design of future clinical trials of antidyskinetic agents...
  92. ncbi [The concept of neuroprotective agents as a treatment modulator in the development of brain diseases]
    Regis Bordet
    EA1046 Département de Pharmacologie, Institut de Médecine Prédictive et de Recherche Thérapeutique, Faculté de Médecine de l Université Lille2 and Centre Hospitalier et Universitaire de Lille, Lille, France
    Therapie 62:463-72. 2007